Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Otonomy, Inc. OTIC
$0.01
На 18:00, 12 мая 2023
+59 900.00%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
582482.00000000
-
week52high
2.51
-
week52low
0.01
-
Revenue
125000
-
P/E TTM
0
-
Beta
1.57172900
-
EPS
-0.06000000
-
Last Dividend
0.11000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Neutral | Buy | 02 авг 2022 г. |
| Oppenheimer | Outperform | Outperform | 21 апр 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 23 февр 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 07 июл 2020 г. |
| Cantor Fitzgerald | Overweight | Overweight | 16 июн 2020 г. |
| Piper Sandler | Neutral | Overweight | 13 окт 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Weber David Allen | D | 285863 | 91636 | 30 дек 2022 г. |
| Cayer Paul E | D | 183733 | 40054 | 28 дек 2022 г. |
| CAPPS VICKIE L | D | 3400 | 42242 | 28 ноя 2022 г. |
| Kennedy Ciara | A | 27500 | 27500 | 21 июн 2022 г. |
| Lichter Jay | A | 27500 | 27500 | 21 июн 2022 г. |
| McGill Iain | A | 27500 | 27500 | 21 июн 2022 г. |
| Schroeder Theodore R | A | 27500 | 27500 | 21 июн 2022 г. |
| BREITMEYER JAMES B | A | 27500 | 27500 | 21 июн 2022 г. |
| Broadfoot Jill Marie | A | 27500 | 27500 | 21 июн 2022 г. |
| CAPPS VICKIE L | A | 27500 | 27500 | 21 июн 2022 г. |
Новостная лента
Why Is Otonomy (OTIC) Stock Up 97% Today?
InvestorPlace
29 ноя 2022 г. в 12:27
Otonomy (NASDAQ: OTIC ) stock is on the move Tuesday despite a lack of news from the biopharmaceutical company. Instead, it looks like traders have latched onto OTIC stock as the next big short squeeze.
Best Penny Stocks To Buy? 7 To Watch Under $1 Right Now
PennyStocks
15 ноя 2022 г. в 12:22
Penny stocks to buy for under $1 but are they worth the risk? The post Best Penny Stocks To Buy?
These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022
24/7 Wall Street
24 окт 2022 г. в 21:21
The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.
Otonomy, Inc. (OTIC) CEO Dave Weber on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
25 июл 2022 г. в 20:18
Otonomy, Inc. (NASDAQ:OTIC ) Q2 2022 Earnings Conference Call July 25, 2022 4:30 PM ET Company Participants Robert Uhl - Managing Director, ICR Westwicke Dave Weber - Chief Executive Officer, President and Board Member Paul Cayer - Chief Financial and Business Officer Conference Call Participants Ken Cacciatore - Cowen and Company Chris Raymond - Piper Sandler Francois Brisebois - Oppenheimer and Company Oren Livnat - H.C. Wainwright & Co. Operator Good day, and thank you for standing by.
Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update
GlobeNewsWire
18 июл 2022 г. в 07:30
SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update at 4:30 p.m. ET on July 25, 2022.